RecruitingPhase 2NCT04792489

DALY II USA/ MB-CART2019.1 for DLBCL

Studying Diffuse large B-cell lymphoma of the central nervous system

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Miltenyi Biomedicine GmbH
Principal Investigator: Johanna Theruvath, MD
Miltenyi Biomedicine GmbH
Intervention: zamtocabtagene autoleucel (MB-CART2019.1)(biological)
Enrollment: 248 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2028

Study locations (25)

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Mayo Clinic, Phoenix, Arizona, United States
UC San Diego Health, La Jolla, California, United States
Stanford University, Stanford, California, United States
Yale University, New Haven, Connecticut, United States
Baptist Health Miami Cancer Institute, Miami, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Robert H Lurie Cancer Center, Chicago, Illinois, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
+10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04792489 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma of the central nervous system

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03277729
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center

See all trials for Diffuse large B-cell lymphoma of the central nervous system →

← Back to all trials